Hims launches Peptides+ with 5 compounded products
- Good news: Peptides+ launched on 18 Nov, ahead of plan, bundled with Care+ lab testing that moves the testing-data loop forward.
- Bad news: None of the 5 products is FDA-approved, and the legal basis is a 'temporary' enforcement discretion of 28 Oct.
- Neutral: Three executives sold about $570,000 under 10b5-1 plans set in May 2026, not a bearish signal.
Read the full notes
Four updates. Peptides+ launched on 18 Nov, ahead of the original 'end of November' plan, with 5 US compounded products. The real point is the bundled Care+: two lab tests a year plus at-home blood draws move the closed loop on testing data a step forward (a positive moat signal).
Read more
None of the 5 products is FDA-approved, the legal basis is the health department's 'temporary' enforcement discretion of 28 Oct, and competitors arrived at the same time (Noom OpenRx, Superpower). On 17 Nov three executives sold about $570,000 in total under 10b5-1 plans set in May 2026, which is not a bearish signal.
Key evidence
- Company press release (Business Wire) and CNBC, 18 Nov: Peptides+ launched on 18 Nov with 5 US compounded products: sermorelin, NAD+, glutathione, vitamin B12 and L-carnitine (L-carnitine is new, not on the earlier list). BPC-157 and TB-500 are still listed as 'available once they meet regulatory standards' and have not been cleared.
- Process: assessment of medical history and goals, a licensed physician trained in peptides sets a personalised plan, a licensed US pharmacy compounds and ships, and the care team follows up regularly to adjust the dose.
- Demand signal: the waitlist opened in late October drew more than 10,000 sign-ups in 15 days (company spokesperson to CNBC). Against 2.788 million subscribers at the end of Q3, that is only about 0.4%, so interest is there but it cannot move the revenue base in the short term.
- Peptides+ must be paired with Care+: two lab tests a year to track results and messaging with a doctor 24 hours a day.
- Men's testing kit: at-home blood draw and 22 biomarkers (testosterone, vitamin D, cholesterol and others). Users whose results suggest they may be suitable can move on to a testosterone therapy assessment, so lab testing feeds customers straight into the men's health specialty.
- Women's testing kit: 22 markers (hormones, vitamins, heart health). It is the first time Hers has offered at-home blood draws.
Show 6 more
- Pricing (media reports, not checked directly because the website blocks scraping): about $150-200 a month for a single treatment, including the mandatory Care+, which costs about $49 a month.
- Risks: none of the 5 products is an FDA-approved product. Hims's chief medical officer told CNBC there is 'not the kind of data we are used to', and patients with serious heart, liver or kidney disease are not being treated for now. Academics at Tufts and UC Davis criticised the doses as having no basis.
- Regulatory basis: the health department's 'temporary' enforcement discretion of 28 Oct, with the Federal Trade Commission lawsuit still ongoing, so compliance risks stack up.
- Competition: Noom (OpenRx, 17 Nov) and Superpower entered at the same time, and several launched together at the HLTH conference. Hims's differentiation is still its own peptide factory, data and cross-selling, and pricing and gross margin are unproven.
- SEC EDGAR Form 4 XML (filed 18 Nov): chief policy officer Autor sold 23,828 shares, chief financial officer Okupe sold 3,518 and chief legal officer Boughton sold 3,458. All were code S (active sales) at an average price of $18.53, about $570,000 in total.
- All three sold under 10b5-1 plans set on 20-21 May 2026. They hold 48,961, 266,188 and 311,190 shares respectively after the sales. The sales are small and the plans were set half a year ago, so this is not a bearish signal.
Catalysts to watch
- Whether Care+ penetration or repeat purchase is disclosed (the key measure of real progress in the testing-data flywheel)
- Whether regulated peptides such as BPC-157 and TB-500 are cleared
- Conversion from the Peptides+ waitlist to paying customers, and expansion of compounded SKUs by year end
- Direction of the health department's temporary enforcement discretion (a tightening would hit the business line directly)
- Progress of the Federal Trade Commission lawsuit
- Pricing and first-customer acquisition data from entrants such as Noom OpenRx and Superpower
Risks
- The 5 products are not FDA-approved, the chief medical officer admits there is not the kind of data the company is used to, patients with serious illness are not being treated, and academics question the basis for the doses
- The legal basis is the health department's 'temporary' enforcement discretion of 28 Oct, so any tightening of policy would hit the peptide business line at once
- The Federal Trade Commission lawsuit is still ongoing, so compliance risks stack up
- Competitors arrived at the same time (Noom OpenRx, Superpower, the HLTH conference), and Hims's pricing and gross margin are unproven
- The 10,000 Peptides+ waitlist sign-ups are only 0.4% of 2.788 million subscribers, so the short-term contribution to the revenue base is limited
Show 2 more
- Care+ penetration and repeat purchase have not been disclosed, so the real strength of the testing-data flywheel is unproven
- Website pricing was blocked by anti-scraping and could not be checked directly, so media-reported prices are for reference only
Sources 4
- Business Wire, company press release, 18 Nov
- CNBC, 18 Nov
- SEC EDGAR Form 4 XML (filed 18 Nov; chief policy officer Autor, CFO Okupe, chief legal officer Boughton)
- Public criticism of the dosing basis by academics at Tufts and UC Davis